7 protocol(s) meet the specified criteria
PI: Dees, E. Claire
Protocol No.TitleStatus
2843-1001A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects with Relapsed/Refractory Advanced and/or Metastatic Solid TumorsOpen
B2151009Phase 1B Study to Assess the Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)Open
H3B-6545-A001-101A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancerOpen
LAO-NCI-9938-CIRBPhase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumorsOpen
NCI10020-CIRBA Phase II Open-Label, Randomized Study of PARP Inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast CancerOpen
NRG-BR003-CIRBA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast CancerOpen
S1418-CIRBPhase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant ChemotherapyOpen